INCLINE VILLAGE, Nev.,
Sept. 19, 2017 /PRNewswire/
-- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today
announced that John P. McLaughlin,
PDL's chief executive officer, will present at the 2017 Cantor
Fitzgerald Global Healthcare Conference in New York City on Tuesday, September 26, 2017, at 10:20 a.m. EDT. PDL's presentation was originally
scheduled for September
25th but was subsequently moved to the
26th.
To access the live and subsequently archived webcasts of the
presentations, go to the company's website at http://www.pdl.com
and go to "Presentations and Events." Please connect to the website
at least 15 minutes prior to the presentations to allow for any
software download that may be necessary. The archived webcasts will
be available for at least seven days following each
presentation.
About PDL BioPharma
PDL seeks to provide a significant
return for its shareholders by acquiring and managing a portfolio
of companies, products, royalty agreements and debt facilities in
the biotech, pharmaceutical and medical device industries. In 2012,
PDL began providing alternative sources of capital through royalty
monetizations and debt facilities, and in 2016, began acquiring
commercial-stage products and launching specialized companies
dedicated to the commercialization of these products. To date, PDL
has consummated 17 such transactions, of which 10 are active and
outstanding. PDL has two debt transactions outstanding,
representing deployed and committed capital of $170.0 million: CareView and kaléo; one hybrid
royalty/debt transaction outstanding, representing deployed and
committed capital of $44.0 million:
Wellstat Diagnostics; and five royalty transactions outstanding,
representing deployed and committed capital of $396.1 million and $397.1
million, respectively: KYBELLA®, AcelRx, University of Michigan, Viscogliosi Brothers and
Depomed. PDL's equity and loan investments in Noden represent
deployed and committed capital of $179.0
million and $202.0 million,
respectively, and its converted equity and loan investment in
LENSAR represents deployed capital of $40
million.
NOTE: PDL, PDL BioPharma, the PDL logo and the PDL
BioPharma logo are trademarks or registered trademarks of, and are
proprietary, to PDL BioPharma, Inc. which reserves all rights
therein.
View original content with
multimedia:http://www.prnewswire.com/news-releases/pdl-biopharma-updates-presentation-time-for-cantor-fitzgerald-conference-300521689.html
SOURCE PDL BioPharma, Inc.